QCM
CAPR icon

Quantinno Capital Management’s Capricor Therapeutics CAPR Stock Holding History

Quantinno Capital Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$357K Buy
14,841
+369
+3% +$11.2K ﹤0.01% 3142
2026
Q1 		$440K Buy
14,472
+2,083
+17% +$55.5K ﹤0.01% 2803
2025
Q4 		$358K Buy
+12,389
New +$162K ﹤0.01% 2715

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Quantinno Capital Management's CAPR Position: Q2 2026 in Review

Quantinno Capital Management increased its Capricor Therapeutics (CAPR) stake by 2.5% in Q2 2026, buying an estimated $11.2K and bringing the position to 14,841 shares worth $357K. The position accounts for ﹤0.01% of the portfolio, ranked #3142.

Quantinno Capital Management first reported a position in CAPR in Q4 2025 and has held it in 3 quarters since. The position peaked at $440K in Q1 2026. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Quantinno Capital Management held 14,841 shares of Capricor Therapeutics worth $357K as of Q2 2026.
  • Quantinno Capital Management bought 369 Capricor Therapeutics shares in Q2 2026, an estimated $11.2K.
  • Capricor Therapeutics made up ﹤0.01% of Quantinno Capital Management's portfolio in Q2 2026, its #3142 holding.
  • Quantinno Capital Management first reported a position in Capricor Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Quantinno Capital Management's Capricor Therapeutics position peaked at $440K in Q1 2026.
  • 169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Quantinno Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.